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Introduction: The hepatocyte growth factor/MET pathway has
been shown to cause tumor progression in several types of carcino-
mas. The aim of this study was to examine the correlations between
c-MET/phospho-MET expression as well asMET gene copy number
alterations and overall survival (OS) in non-small cell lung carcino-
mas (NSCLCs).
Methods: We analyzed 906 NSCLCs including 704 adenocarcino-
mas (ADCs), 150 squamous cell carcinomas (SCCs), 43 sarcoma-
toid carcinomas, and 9 large cell carcinomas. The mutational status
of epidermal growth factor receptor and K-ras and anaplastic lym-
phoma kinase rearrangements were retrospectively examined. We
performed immunohistochemistry to detect c-MET/phospho-MET
expression and MET gene copy number using bright-field in situ
hybridization (BISH).
Results: c-MET/phospho-MET expression and MET BISH positiv-
ity were observed in 22.2%, 5.6%, and 10.9% of NSCLCs, respec-
tively; they were more prevalent in ADCs (27.3%, 6.9%, and 11.5%,
respectively) and sarcomatoid carcinomas (20.9%, 9.3%, and
36.6%, respectively) than in SCCs and large cell carcinomas.
Among ADCs, poorly differentiated cases exhibited c-MET expres-
sion and MET BISH positivity more commonly than well-differen-
tiated ones. An analysis of all patients revealed that c-MET/phos-
pho-MET expression and MET BISH positivity were not correlated
with OS. However, when SCC cases were excluded, both univariate
(p  0.019) and multivariate (p  0.020) analyses revealed a
significant correlation between MET BISH positivity and OS.
Conclusions: c-MET/phospho-MET expression and MET BISH
positivity differed according to histological type. Among ADCs,
c-MET expression and MET BISH positivity were more common in
poorly differentiated cases. MET BISH positivity was an indepen-
dent prognostic factor in nonsquamous NSCLCs.
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The c-MET is a high-affinity receptor for hepatocytegrowth factor (HGF), a disulfide-linked heterodimeric
molecule mainly produced by mesenchymal cells.1,2 HGF
binds to c-MET receptor and undergoes phosphorylation on
intracellular tyrosine residues, which leads to the activation
of downstream signaling.2 Among these tyrosine residues,
Tyr1234/1235 is one of the major phosphorylation sites.
Signaling through the HGF/MET pathway results in tumor
growth, angiogenesis, and the development of invasive phe-
notypes in several types of malignancy, making this pathway
an attractive target for potential treatment.3
In lung cancers, c-MET protein is reportedly expressed in
up to 70% of adenocarcinomas (ADCs) and 40% of squamous
cell carcinomas (SCCs); it is also associated with advanced
tumor stage and poor clinical outcome.4–6 Similar to c-MET
protein expression, MET gene amplification is an independent
unfavorable prognostic factor in surgically resected non-small
cell lung carcinomas (NSCLCs).7,8 In addition, MET gene am-
plification is reported to be associated with 20% of lung ADCs
with acquired resistance against epidermal growth factor recep-
tor (EGFR)-tyrosine kinase inhibitor (TKI).9,10
MET gene amplification has been analyzed in NSCLCs
by various assays including real-time polymerase chain reaction,
comparative genomic hybridization, and fluorescence in situ
hybridization (FISH); its frequency is reported to range from 1.1
to 21%.7,8,11–14 Among these methods, FISH is considered the
standard method for assessing gene copy number. However, the
main disadvantage of FISH is that the fluorescent signals fade
over time. Recently, bright-field in situ hybridization (BISH)
was tested as an emerging alternative method for assessing gene
copy number alterations of various genes including human
epidermal growth factor 2 (HER2)15 and EGFR. The advantage
of BISH is that it enables the evaluation of slides by light
microscopy, which allows the simultaneous visualization of
amplified signals and cell morphology.
In this study, we analyzed the expression of c-MET and
phospho-MET (Tyr1234/1235) by immunohistochemistry
and MET gene copy number alterations by BISH. We also
analyzed the correlations between c-MET/phospho-MET ex-
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pression and MET gene copy number alterations, the clinico-
pathological parameters including the status of EGFR and
K-ras mutations, and the anaplastic lymphoma kinase (ALK)
rearrangements.
PATIENTS AND METHODS
Case Selection
The institutional review board approved the study. The
specimens used in this study were from 906 patients who
underwent lung resection for ADC, SCC, large cell carci-
noma (LCC), or sarcomatoid carcinoma (SAC) at the Na-
tional Cancer Center Hospital (Tokyo, Japan) from 1997 to
2007. Histological diagnosis was based on the scheme of the
latest World Health Organization classification16 with the aid
of immunohistochemical panels.17 Furthermore, ADC and
SCC cases were graded on the basis of differentiation in a
three-tiered system. For ADC, well-differentiated tumors
were consistent with predominant lepidic or papillary pat-
terns, moderately differentiated tumors were consistent with a
predominant acinar pattern, and poorly differentiated tumors
were consistent with a solid growth pattern. For SCC, well-
differentiated tumors had an obvious stratified pattern, vari-
ous uniform or slight pleomorphic nuclei, and significant
keratinization; moderately differentiated tumors had a strati-
fied pattern, although the degree of stratification and kerati-
nization was lower than that of the well-differentiated tumors;
poorly differentiated tumors primarily exhibited solid growth
and only had focal-stratified patterns and keratinization.
We collected the patients’ age, gender, smoking his-
tory, treatment modalities, outcomes, maximum tumor size
(in centimeter), and pathologic stage (p-stage). Staging was
based on the guidelines of the seventh edition of the tumor,
node, metastasis classification for lung cancer.18
Microarray Construction
The most representative tumor areas were sampled for
tissue microarray. The tissue microarrays were assembled
with a tissue-arraying instrument KIN-1 (Azumaya, Tokyo,
Japan). To reduce sampling bias due to tumor heterogeneity,
we used duplicate core samples measuring 2.0 mm in diam-
eter taken from two different portions of a tumor.
Immunohistochemistry
For c-MET immunohistochemical staining, the Bench-
Mark XT automated slide processing system (Ventana, Tucson,
AZ) was used according to the manufacturer’s protocol. In brief,
after the tissue sections were deparaffinized using EZ Prep
(Ventana), heat-induced epitope retrieval with CC1 (Ventana)
was performed, and the slides were incubated with primary
antibodies against c-MET (CONFIRMAnti-Total c-MET, clone
SP44; Ventana). Immunoreactions were detected using the ul-
traView DAB Universal Detection Kit followed by counter-
staining with Hematoxylin II (Ventana) and Bluing Reagent
(Ventana). For phospho-MET (Tyr1234/1235) immunohisto-
chemical staining, heat-induced epitope retrieval with Target
Retrieval Solution (pH 9.0) (Dako Corporation, Carpinteria,
CA) was performed. The slides were subsequently incubated
with primary antibodies against phospho-MET (1:200, D26;
Cell Signaling Technology, Danvers, MA) for 1 hour at room
temperature. Immunoreactions were detected using the Envison-
Plus system (Dako Corporation), visualized with 3,3-diamino-
benzidine, and then counterstained with hematoxylin. For
c-MET, immunopositive cases were defined as those exhibiting
cytoplasmic and/or membranous staining in 10% of cells
(Figure 1A). For phospho-MET, immunopositive cases were
defined as those exhibiting membranous staining in 10% of
cells.
BISH Analysis
The dual-color BISH assay for MET and chromosome
7 centromere (CEN7) DNA targets was performed using a
sequential hybridization method15 on the BenchMark XT
system (Ventana). In brief, after deparaffinization using EZ
Prep (Ventana), the tissue sections were subjected to heat-
induced target retrieval using CC2 (Ventana) and digested
FIGURE 1. Representative images of a c-MET- and phospho-MET-positive case of adenocarcinoma. A, Positive staining of
c-MET with brown-stained membranes and cytoplasm (original magnification, 200). B, Positive staining of phospho-MET
with brown-stained membranes (original magnification, 200).
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with in situ hybridization (ISH) Protease 3 (Ventana). Then,
the tissue samples were hybridized with INFORMMET DNA
Probe (Ventana), a dinitrophenyl-labeled nick-translated re-
peat-deleted DNA probe, for 6 hours. After stringency
washes with 2 saline-sodium citrate buffer (Ventana), MET
probe hybridization sites were visualized with ultraView
silver in situ hybridization detection kit (Ventana). For CEN7
detection, the tissue sections were hybridized with INFORM
Chromosome 7 Probe (Ventana), a dinitrophenyl-labeled oli-
goprobe, for 2 hours. The CEN7 ISH signal was detected with
the ultraView Red ISH detection kit. Counterstaining was
performed using Hematoxylin II (Ventana) and Bluing Re-
agent (Ventana).
We evaluated the BISH signals for each locus-specific
BISH probe at 400 and 600 magnification using an
Olympus BX50 microscope (Olympus, Tokyo, Japan). The
copy number per cell was counted in 50 nonoverlapping
tumor cell nuclei. On the basis of the International Union
Against Cancer criteria for EGFR,19 tumors were classified
into two groups—BISH positive and BISH negative—ac-
cording to the frequency of tumor cells with specific copy
numbers of theMET gene and CEN7. A BISH-positive tumor
was defined as a tumor meeting one of the five categories of
MET gene status: MET gene amplification (MET to CEN7
ratio 2, 15 copies of the MET signal in 10% of tumor
cells, small gene clusters [4–10 copies each] in 10% the
tumor cells, or innumerable tight gene clusters in 10% the
tumor cells) and high polysomy (40% of cells exhibiting
4 copies of the MET signal). Otherwise, the tumor was
defined as BISH negative.
Analysis of EGFR and K-ras Mutational Status,
ALK Rearrangement, and EGFR-TKI Response
We detected two common EGFR mutations (deletions
in exon 19 [DEL] and a point mutation at codon 858 in exon
21 [L858R]) and K-ras mutations (in exons 1 and 2) using a
high-resolution melting analysis routinely performed at our
institution.20 Echinoderm microtubule-associated protein-like
4 (EML4) and ALK fusions were analyzed by immunohisto-
chemistry, reverse-transcriptase polymerase chain reaction,
and/or BISH assay. Of the 906 cases, 110 received systemic
therapy with EGFR-TKI gefitinib (250 mg daily) after tumor
relapse or because of advanced stage. The clinical response to
gefitinib was determined according to the Response Evalua-
tion Criteria in Solid Tumors.21 In this study, the complete
response and partial response cases were categorized as
responders, whereas the stable disease and progressive dis-
ease cases were categorized as nonresponders.
Statistical Analysis
Statistical analysis was performed using SPSS 12.0 for
Windows (SPSS, Chicago, IL). Student t test and the 2 test
were used for continuous and categorical variables, respec-
tively. Progression-free survival and overall survival (OS)
curves were calculated using the Kaplan-Meier method. The
curves were compared using the log-rank test. Univariate
survival analysis was performed with log-rank test and Cox’s
proportional hazard regression. In the multivariate Cox
model, variables with p value less than 0.10 from Wald’s test
for univariate models were included. Statistical significance
was set at p less than 0.05.
RESULTS
Clinicopathologic Background
A total of 906 cases were included as follows: 704 ADCs
(291 well differentiated, 275 moderately differentiated, and 138
poorly differentiated histology), 150 SCCs (53 well differenti-
ated, 51 moderately differentiated, and 46 poorly differentiated
histology), 9 LCCs, and 43 SACs. There were 332 women and
574 men. The patients’ mean age at the time of diagnosis was
61.7 years (range, 30–88 years). Regarding smoking status, 416
were never-smokers and 490 were smokers. Tumor sizes ranged
from 0.5 to 15.5 cm (mean, 3.53 cm). Lymph node status was
recorded in 890 cases, and metastasis was present in 358.
Regarding p-stage, 432, 226, 218, and 22 cases were at p-stages
I, II, III, and IV, respectively. The mean and median follow-up
times for all 906 patients was 53.3 months (range, 0.3–150
months) and 50.3 months, respectively, with 559 still alive
(mean and median follow-up times were 66.5 and 61.3 months,
respectively).
c-MET and Phospho-MET Protein Expression
by Immunohistochemistry
c-MET expression was observed in 196 (22.2%) of 883
NSCLCs (Figures 1A, B). The c-MET-positive cases were
significantly correlated with a histological subtype (p 
0.001): 186 (27.3%) of 682 ADCs, 1 (0.7%) of 149 SCCs, 0
(0%) of 9 LCCs, and 9 (20.9%) of 43 SACs. In ADCs,
c-MET-positive cases were significantly correlated with his-
tological grade (p  0.002): 32 (11.6%) of 276 with well-
differentiated, 42 (15.6%) of 270 with moderately differen-
tiated, and 34 (25.2%) of 135 with poorly differentiated
histology. c-MET-positive tumors were more common in
younger patients (p  0.009) and were smaller (p  0.001)
than c-MET-negative tumors (Table 1). c-MET expression
was not associated with gender, lymph node status, p-stage,
EGFR or K-ras mutational status, or ALK rearrangements.
Phospho-MET expression was observed in 51 (5.8%)
of 880 NSCLCs. The phospho-MET-positive cases were
significantly correlated with the histological subtype (p 
0.006): 47 (6.9%) of 678 ADCs, 0 (0%) of 150 SCCs, 0 (0%)
of 9 LCCs, and 4 (9.3%) of 43 SACs. In contrast to c-MET
expression in ADCs, phospho-MET expression was not as-
sociated with histological grade (p  0.726): 17 (6.1%) of
277 with well-differentiated, 21 (7.9%) of 267 with moder-
ately differentiated, and 9 (6.7%) of 134 with poorly differ-
entiated histology. Phospho-MET-positive tumors were more
common in never-smokers (p  0.013) and smaller (p 
0.001) than phospho-MET-negative tumors (Table 1). Phos-
pho-MET expression was not associated with gender, age,
lymph node status, p-stage, EGFR or K-ras mutational status,
or ALK rearrangements (Table 1).
There was a significant association between c-MET and
phospho-MET expression among the 864 cases for which
both c-MET and phospho-MET data were available (p 
0.001). However, only 34 (30.1%) of 113 cases exhibited
dual positivity.
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MET BISH-Positive Cases
Of all NSCLCs, 92 (10.9%) of 844 cases were MET
BISH-positive (Figure 2). Among them, 64 (69.6%) cases
exhibited high polysomy and 28 (30.4%) exhibited gene
amplification. MET BISH-positive cases were significantly
correlated with histological subtype (p  0.001): 75 (11.5%)
of 655 ADCs, 1 (0.7%) of 142 SCC, 1 (16.7%) of 6 LCCs,
and 15 (36.6%) of 41 SACs. Among ADCs, MET BISH-
positive cases were significantly correlated with histological
grade (p  0.001): 18 (6.8%) of 265 with well-differentiated,
32 (12.2%) of 262 with moderately differentiated, and 25
(19.5%) of 128 with poorly differentiated histology. MET
BISH positivity was not associated with gender, age, smoking
status, lymph node status, p-stage, EGFR or K-ras mutational
status, or ALK rearrangements (Table 2).
Association between MET Status and EGFR-TKI
Response
Among the 109 patients who received systemic therapy
with EGFR-TKI gefitinib, the therapeutic effect of gefitinib
was complete response in 3 patients, partial response in 53
patients, stable disease in 15 patients, and progressive disease
in 38 patients. The background data of these 109 patients are
as follows: 50 women and 59 men, 74 never-smokers and 35
former or present smokers, 108 ADCs and 1 SAC, 74 EGFR
mutated and 35 wild type, and 3 K-ras mutated and 64 wild
TABLE 1. Patients Characteristics According to c-MET and Phospho-MET Expression Status
Variables
c-MET Phospho-MET
Negative (%) Positive (%) p Negative (%) Positive (%) p
Gender
Male 443 (78.7) 120 (21.3) 0.401 534 (94.3) 32 (5.7) 0.880
Female 244 (76.3) 76 (23.8) 295 (93.9) 19 (6.1)
Age (yr)
Median 62.1 60.2 0.009 61.8 60.0 0.189
Range 30–88 30–82 30–88 30–80
Smoking
Never 305 (75.5) 99 (24.5) 0.144 368 (92) 32 (8.0) 0.013
Former/present 382 (79.7) 97 (20.3) 461 (96.0) 19 (4.0)
Tumor size (cm)
Median 3.65 3.20 0.001 3.6 2.7 0.001
Range 0.5–15 0.8–9.5 0.5–15 0.8–7
Lymph node status
Negative 392 (76.1) 123 (23.9) 0.214 485 (94.5) 28 (5.5) 0.657
Positive 281 (79.8) 71 (20.2) 329 (93.7) 22 (6.3)
Stage
I  II 485 (78.0) 137 (22.0) 0.718 582 (93.9) 38 (6.1) 0.627
III  IV 188 (76.7) 57 (23.3) 232 (95.1) 12 (4.9)
Histology
Adenocarcinoma 496 (72.7) 186 (27.3) 0.001 631 (93.1) 47 (6.9) 0.006
Squamous cell carcinoma 148 (99.3) 1 (0.7) 150 (100) 0 (0)
Large cell carcinoma 9 (100) 0 9 (100) 0 (0)
Sarcomatoid carcinoma 34 (79.1) 9 (20.9) 39 (90.7) 4 (9.3)
c-MET expression
Negative 667 (98.8) 8 (1.2) 0.001
Positive 148 (77.9) 42 (22.1)
EGFR
Wild type 281 (73.9) 99 (26.1) 0.802 350 (94.3) 21 (5.7) 0.190
Mutation 256 (72.9) 95 (27.1) 326 (91.8) 29 (8.2)
K-ras
Wild type 436 (72.3) 167 (27.7) 0.064 560 (92.7) 44 (7.3) 0.345
Mutation 68 (81.9) 15 (18.1) 76 (96.2) 3 (3.8)
ALK
Wild type 519 (73.6) 186 (26.4) 0.814 652 (92.9) 50 (7.1) 0.391
Rearranged 17 (70.8) 7 (29.2) 22 (100) 0 (0)
EGFR-TKI
Nonresponder 35 (68.6) 16 (31.4) 0.513 46 (93.9) 3 (6.1) 1.00
Responder 41 (75.9) 13 (24.1) 48 (92.3) 4 (7.7)
EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor.
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type. Among them, only EGFR mutational status was corre-
lated with EGFR-TKI response (p  0.001).
The expression of c-MET and phospho-MET was ob-
served in 13 (24.1%) of 54 responders and 7 (7.7%) of 52
responders, respectively; MET BISH positivity was observed
in 4 (8.3%) of 48 responders. No significant correlation was
observed between c-MET/phospho-MET expression or MET
BISH positivity and EGFR-TKI response.
In a univariate analysis of the patients who received
systemic therapy with EGFR-TKI gefitinib, c-MET expres-
sion (hazard ratio [HR]  0.897, 95% confidence interval
[95% CI]  0.581–1.385; p  0.625), phospho-MET expres-
sion (HR  0.884, 95% CI  0.407–1.922; p  0.756), and
MET BISH positivity (HR  1.372, 95% CI  0.743–2.536;
p  0.330) were not correlated with progression-free sur-
vival. In addition, c-MET expression (HR  1.210, 95%
CI  0.727–2.013; p  0.464), phospho-MET expression
(HR  0.884, 95% CI  0.407–1.922; p  0.186), and MET
BISH positivity (HR  1.777, 95% CI  0.758–4.167; p 
0.798) were not correlated with OS.
Association between MET BISH Positivity and
c-MET/Phospho-MET Protein Expression
A statistically significant association between c-MET
expression and MET BISH positivity was found among the
830 cases for which both c-MET immunohistochemistry and
BISH data were available (Table 2, p 0.001). However, the
frequency of dual positivity was not high: only 55 (28.8%) of
191 c-MET-positive cases were MET BISH positive.
A statistically significant association between phospho-
MET and MET BISH positivity was found among the 824
cases for which both phospho-MET immunohistochemistry
and BISH data were available (Table 2, p 0.004). However,
the frequency of dual positivity was not high; MET BISH
positivity was observed only in 15 (30%) of 50 phospho-
MET-positive cases. Five (10.2%) phospho-MET-positive
tumors exhibited neither c-MET nor MET BISH positivity.
Survival Analysis
To investigate the prognostic importance of c-MET/
phospho-MET expression and MET BISH positivity, the
univariate and multivariate survival analyses were performed
using the Cox proportional hazard model; the variables in-
cluded gender, smoking history, lymph node status, p-stage,
FIGURE 2. Representative image of a bright-field in situ
hybridization (BISH)-positive case of sarcomatoid carcinoma.
Amplified MET gene signals appear as clusters of black dots
and two to four CEN7 signals as red dots in the nuclei (orig-
inal magnification, 400).
TABLE 2. Patients Characteristics According to MET
Amplification Status
Variables
MET BISH
Negative (%) Positive (%) p
Gender
Male 471 (88.5) 61 (11.5) 0.567
Female 281 (90.1) 31 (9.9)
Age (yr)
Median 61.6 62.3 0.477
Range 30–88 38–82
Smoking
Never 353 (89.8) 40 (10.2) 0.580
Former/present 399 (88.5) 52 (11.5)
Tumor size (cm)
Median 3.5 3.7 0.242
Range 0.5–15 1.3–8.5
Lymph node status
Negative 444 (90.2) 48 (9.8) 0.214
Positive 296 (87.3) 43 (12.7)
Stage
I  II 538 (90.1) 59 (9.9) 0.138
III  IV 202 (86.3) 32 (13.7)
Histology
Adenocarcinoma 580 (88.5) 75 (11.5) 0.001
Squamous cell carcinoma 141 (99.3) 1 (0.7)
Large cell carcinoma 5 (83.3) 1 (16.7)
Sarcomatoid carcinoma 26 (63.4) 15 (36.6)
c-MET expression
Negative 602 (94.2) 37 (5.8) 0.001
Positive 136 (71.2) 55 (28.8)
Phospho-MET expression
Negative 699 (90.3) 75 (9.7) 0.001
Positive 35 (70.0) 15 (30.0)
EGFR
Wild type 314 (86.7) 48 (13.3) 0.821
Mutation 295 (87.5) 42 (12.5)
K-ras
Wild type 503 (86.3) 80 (13.7) 0.205
Mutation 71 (92.2) 6 (7.8)
ALK
Wild 586 (86.7) 90 (13.3) 0.341
Rearranged 21 (95.5) 1 (4.5)
EGFR-TKI
Nonresponder 39 (83.0) 8 (17.0) 0.232
Responder 44 (91.7) 4 (8.3)
BISH, bright-field in situ hybridization; EGFR, epidermal growth factor receptor;
ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor.
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c-MET/phospho-MET expression, and MET BISH status. In
the univariate analysis of all patients, male gender (HR 
1.530, 95% CI  1.214–1.930; p  0.001), former/present
smoking history (HR  1.535, 95% CI  1.233–1.910; p 
0.001), lymph node metastasis (HR  3.507, 95% CI 
2.808–4.382; p  0.001), and advanced p-stage (III or IV)
(HR  3.052, 95% CI  2.461–3.785; p  0.001) were
significantly associated with a higher risk of death (Table 3).
Among nonsquamous NSCLCs, male gender (HR 
1.5148, 95% CI  1.125–1.864; p  0.004), former/present
smoking history (HR  1.460, 95% CI  1.145–1.861; p 
0.002), lymph node metastasis (HR 4.024, 95% CI 3.102–
4.024; p  0.001), advanced p-stage (III or IV) (HR  3.276,
95% CI  2.565–4.184; p  0.001), and MET BISH positivity
(Figure 3) (HR  1.508, 95% CI  1.066–2.134; p  0.020)
were significantly associated with a higher risk of death (Table
3). Multivariate analysis of nonsquamous NSCLCs revealed that
lymph node metastasis (HR  3.030, 95% CI  2.158–4.255;
p  0.001), advanced p-stage (III or IV) (HR  1.625, 95%
CI  1.183–2.233; p  0.003), and MET BISH positivity
(HR  1.544, 95% CI  1.083–2.202; p  0.016) were
independent prognostic factors (Table 4).
When analyzing advanced-stage disease in all patients,
c-MET expression (HR  1.099, 95% CI  0.744–1.622;
p  0.637), phospho-MET expression (HR  1.165, 95%
CI  0.593–2.289; p  0.657), and MET BISH positivity
(HR  1.468, 95% CI  0.911–2.365; p  0.115) were not
correlated with OS.
DISCUSSION
This study is one of the largest studies exploring the
roles of c-MET/phospho-MET expression and MET gene
copy number using the novel technology BISH in surgically
resected NSCLCs naive to EGFR-TKIs. c-MET/phospho-
MET expression and MET BISH positivity in NSCLCs were
observed in 22.2%, 5.6%, and 10.9% of cases, respectively.
They were more common in ADCs (27.3%, 6.9%, and 11.5%,
respectively) and SACs (20.9%, 9.3%, and 36.6%, respec-
tively) than in SCCs and LCCs.
Most studies analyzing c-MET expression by immuno-
histochemistry only include ADC histology; reported expres-
sion rates ranged between 24.0% and 74.6%.6,22–24 The pos-
sible reasons for this wide range are the application of
different antibodies and/or different scoring methods. In this
study, we used an SP44 clone to recognize the carboxyl
domain of the transmembrane domain. In addition, our
threshold of c-MET positivity was set at strong cytoplasmic
and/or membranous staining 10% of cells, which may be
more strict than that in previous studies. Consistent with other
reports, our analysis of NSCLCs revealed that c-MET expres-
sion is more common in ADCs than in SCCs.4,22
Phospho-MET expression was observed in 51 (5.8%)
of 880 NSCLCs and was more common in ADCs (6.9%) and
SACs (9.3%). The phospho-MET expression rate in ADCs
ranges from 7.0 to 21.5% in the previous reports.6,25 We
found that c-MET expression was significantly correlated
with phospho-MET expression. However, not all c-MET-
positive cases were phospho-MET positive and vice versa;
this is possible because there are several different mecha-
nisms of c-MET and phospho-MET activations.26 The over-
expression of c-MET alone does not seem to be sufficient to
activate c-MET (phospho-MET expression) cascades. MET
may also be activated by MET gene mutations.
The present MET BISH positivity rate of 10.9% in
NSCLCs is within the range of previously reportedMET gene
amplification rates (1.1–21%).7,8,11–14,25,27 Consistent with
some of the previous studies, our results show that MET
BISH positivity was more common in ADCs than in SCCs.12
In contrast to our results, Go et al.14 report that MET ampli-
fication is more common in patients with SCC than in those
with ADC. Okuda et al.7 did not observe any correlation
between MET amplification and the histological type of lung
cancers. We found that in addition to MET BISH positivity,
the expression of MET gene products, namely, c-MET/phos-
TABLE 3. Impacts of Valuables on Patient Overall Survival Estimated by the Cox’s Univariate Analysis
Variables
All Cases Nonsquamous NSCLC
HR 95% CI p HR 95% CI p
Gender
Male vs. female 1.530 1.214–1.930 0.001 1.148 1.1255–1.864 0.004
Smoking
Former/present vs. never 1.535 1.233–1.910 0.001 1.460 1.145–1.861 0.002
Lymph node status
Positive vs. Negative 3.507 2.808–4.382 0.001 4.024 3.102–5.220 0.001
Stage
III IV vs. I  II 3.052 2.461–3.785 0.001 3.276 2.565–4.184 0.001
c-MET expression
Positive vs. negative 0.831 0.631–1.095 0.189 0.942 0.683–1.255 0.684
Phospho-MET expression
Positive vs. negative 0.857 0.518–1.417 0.547 0.944 0.569–1.568 0.825
MET BISH
Positive vs. negative 1.295 0.923–1.818 0.135 1.508 1.066–2.134 0.019
BISH, bright-field in situ hybridization; NSCLC, non-small cell carcinoma; HR, hazard ratio; CI, confidence interval.
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FIGURE 3. Overall survival (OS) analysis. A, OS curves for patients with c-MET-negative (solid line) and c-MET-positive
(dashed line) non-small cell lung carcinomas (NSCLCs) (p  0.189). B, OS curves for patients with c-MET-negative (solid line)
and c-MET-positive (dashed line) nonsquamous NSCLCs (p  0.684). C, OS curves for patients with phospho-MET-negative
(solid line) and phospho-MET-positive (dashed line) NSCLCs (p  0.547). D, OS curves for patients with phospho-MET-nega-
tive (solid line) and phospho-MET-positive (dashed line) nonsquamous NSCLCs (p  0.825). E, OS curves for patients with
MET BISH-negative (solid line) and MET BISH-positive (dashed line) NSCLCs (p  0.135). F, OS curves for patients with MET
BISH-negative (solid line) and MET BISH-positive (dashed line) nonsquamous NSCLCs (p  0.019).
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pho-MET, was correlated with histological type. Another
possible reason for this is accuracy of the histological diag-
nosis as it can be difficult to distinguish between the structure
of poorly differentiated ADCs and SCCs; low interobserver
agreement occurs even among experienced lung patholo-
gists.28 In our cohort, especially in poorly differentiated
NSCLCs, histological typing was confirmed by using immu-
nohistochemical markers.17 These results indicate that c-MET
expression and MET gene amplification are differentiation
markers between ADCs and SCCs.
Poorly differentiated ADCs more commonly exhibit
c-MET expression and MET gene amplification than well-
differentiated ones. Similar to previous reports, moderately or
poorly differentiated ADCs exhibited higher stages. How-
ever, there were no significant differences between p-stage
and c-MET/phospho-MET expression or MET BISH positiv-
ity. These results may indicate that MET cascades affect
tumor differentiation rather than tumor progression. In con-
trast to our results, other groups report that c-MET immuno-
reactivity is correlated with well-differentiated histology.6,22
Paradoxically, c-MET expression is also reported to be asso-
ciated with advanced tumor stage and poor clinical out-
comes.4–6 The results of the present and previous studies
indicate that MET gene amplification is more prevalent in
poorly differentiated ADCs than in well-differentiated ones.8
We also frequently detected c-MET/phospho-MET ex-
pression and MET BISH positivity in SACs. There are no
accounts regarding c-MET expression and MET gene ampli-
fication in pulmonary SACs. Other researchers have grouped
SACs with LCCs/undifferentiated carcinomas or other types
for analysis. In fact, Tsao et al.22 observed c-MET protein
expression in 21% of large/undifferentiated carcinomas be-
fore the publication of the World Health Organization third
edition guidelines in which SAC was defined as an indepen-
dent histological type for the first time.29 Although SACs are
smoking-related carcinomas, phospho-MET-positive tumors
were more common in never-smokers (p  0.013), and
c-MET expression and MET BISH positivity were not corre-
lated with smoking status. In addition, SACs were usually
more than 5 cm, and c-MET/phospho-MET-positive tumors
were smaller (p  0.001) than c-MET/phospho-MET-nega-
tive tumors. c-MET is considered to be an epithelial-mesen-
chymal transition promoter that acts through Src activation.
Epithelial-mesenchymal transition, a process essential to em-
bryonic gastrulation, is proposed as a histogenetic mechanism
for the anaplasia of undifferentiated carcinomas or SACs.30
This is because 24 to 56% of SACs originate from ADCs,31
and both the epithelial and sarcomatoid components of SACs
originate from a single clone.32 c-MET alterations seem to
cause the conversion of ADCs to mesenchyme-like cells.
The present survival analysis indicates that c-MET/
phospho-MET expression and MET BISH positivity are not
correlated with OS in NSCLC cases. However, when analyzing
nonsquamous NSCLCs, MET BISH positivity was significantly
correlated with OS. In addition, the multivariate analysis re-
vealed thatMET BISH positivity was an independent prognostic
factor. Similar to our results, other researchers report that MET
amplification is not correlated with unfavorable outcomes in
NSCLC cases.11,13,14 However, an analysis of ADCs alone
indicates that MET gene amplification is correlated with unfa-
vorable outcomes.11 Meanwhile, other groups report a correla-
tion betweenMET gene amplification and unfavorable outcomes
in NSCLCs.8 The main reasons for this seem to be due to the
differences regarding methods, interpretation criteria, and pa-
tient cohorts, especially with respect to the proportion of poorly
differentiated ADCs.
c-MET/phospho-MET expression and MET BISH posi-
tivity were not associated with EGFR orK-rasmutations or ALK
rearrangements; these findings are not mutually exclusive. Pre-
vious reports indicate that MET amplification is correlated with
acquired EGFR-TKI resistance.9,27 However, we did not find a
correlation between MET BISH positivity and primary EGFR-
TKI resistance. One of the reasons why we did not find a
correlation might be the fact that we analyzed primary EGFR-
TKI resistance and not acquired resistance. More recently,Wu et
al.33 reported that MET gene amplification status is not predic-
tive of the efficacy of first-line EGFR-TKI therapy. In addition,
comparing the ratio of MET-amplified cases between EGFR-
TKI-naive NSCLC and EGFR-TKI-resistant cell line models,
Engelman et al.9 suggest thatMET gene amplification only plays
a limited role in primary resistance to EGFR-TKI. On the other
hand, Turke et al.34 report that the existence of a subpopulation
of MET-amplified cells before drug exposure and HGF acceler-
ate the development of EGFR-TKI resistance through MET
amplification.
In summary, c-MET/phospho-MET expression and MET
BISH positivity were detected in 22.2%, 5.6%, and 10.9% of
NSCLC cases, respectively. MET BISH positivity and c-
MET/phospho-MET expression were significantly correlated
with the histological type, especially ADCs and SACs, and
were more prevalent in poorly differentiated ADCs. MET
BISH positivity is an independent prognostic factor in nons-
quamous NSCLCs.
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